SCHEMBL8767883

SCHEMBL8767883

CC(=O)OCc1ccnc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
ALDH1A1 P00352 2/20 0.49
LOX P28300 1/20 0.49
LOXL3 P58215 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
CYP3A4 P08684 1/20 0.46
GRM5 P41594 1/20 0.43
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX1 P07099 1/20 0.39
NOTUM Q6P988 1/20 0.39
CA2 P00918 1/20 0.39
SMARCA2 P51531 2/20 0.39
SMARCA4 P51532 2/20 0.39
MGMT P16455 1/20 0.38
FFAR1 O14842 1/20 0.38
POLB P06746 1/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20954526 0.84 RECQL (0.47) RECQLALDH1A1LOXLOXL3LOXL2
SCHEMBL27752247 0.84 RECQL (0.50) RECQLALDH1A1LOXLOXL3LOXL2
SCHEMBL23358049 0.84 RECQL (0.50) RECQLALDH1A1LOXLOXL3LOXL2
SCHEMBL28775209 0.83 RECQL (0.53) RECQLLOXLOXL3LOXL2GRM5
SCHEMBL501663 0.81 ALDH1A1 (0.50) ALDH1A1CYP3A4GRM5NPSR1CA2
SCHEMBL29882713 0.81 RECQL (0.44) RECQLALDH1A1LOXLOXL3LOXL2
SCHEMBL9035534 0.80 ALDH1A1 (0.49) ALDH1A1CYP3A4NPSR1MEN1KMT2A
SCHEMBL23960219 0.80 ALDH1A1 (0.49) ALDH1A1CYP3A4KMT2ACA2
SCHEMBL1886874 0.77 RECQL (0.58) RECQLALDH1A1LOXLOXL3LOXL2
SCHEMBL1145877 0.77 LOX (0.57) RECQLALDH1A1LOXLOXL3LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421193-B2 GPR52 modulators and methods of use NEUROCRINE BIOSCIENCES, INC. (US) 2025-09-23 US disclosed
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-07-27 US disclosed
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-07-27 US disclosed
EP-4139284-A1 GPR52 MODULATORS AND METHODS OF USE Neurocrine Biosciences, Inc. (US) 2023-03-01 EP disclosed
WO-2021216705-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
WO-2021216705-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
EP-0627421-B1 Method of preparing 2-chloro-pyridinemethanol CENTRAL GLASS CO LTD (JP) 1997-08-13 EP disclosed
US-5440047-A Method of preparing 2-chloro-pyridinemethanol CENTRAL GLASS COMPANY, LIMITED (JP) 1995-08-08 US disclosed
EP-0627421-A1 Method of preparing 2-chloro-pyridinemethanol CENTRAL GLASS COMPANY, LIMITED (JP) 1994-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE GPR52, GPR68, GPR35 RECQL 2117/4885ALDH1A1 1831/4885LOX 2631/4885
US-12421193-B2 GPR52 modulators and methods of use GPR52, GPR68, GPR35 RECQL 2117/4885ALDH1A1 1831/4885LOX 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.